Expert Insights: Practice-Changing GU Oncology Trials from ASCO GU26 with Dr. Yüksel Ürün скачать в хорошем качестве

Expert Insights: Practice-Changing GU Oncology Trials from ASCO GU26 with Dr. Yüksel Ürün

👉 Visit https://oncoassist.com/ to streamline patient care with cutting-edge tools, treatment protocols, and calculators! 🔬In this episode of Oncology Spotlight - Expert Insights, Dr Yüksel Ürün, medical oncologist at Ankara University, reviews key studies presented at the ASCO Genitourinary Cancers Symposium, 2026. The discussion focuses on clinically relevant trial results across bladder cancer, kidney cancer, and metastatic prostate cancer, highlighting data that may influence treatment decisions in daily oncology practice. Key Studies Discussed: • KEYNOTE-B15 trial – Enfortumab vedotin + pembrolizumab in muscle-invasive bladder cancer- https://www.asco.org/abstracts-presen... • LITESPARK-011 – Belzutifan + lenvatinib after IO therapy in kidney cancer - https://www.asco.org/abstracts-presen... • LITESPARK-022 – Adjuvant belzutifan + pembrolizumab in high-risk kidney cancer - https://www.asco.org/abstracts-presen... • BRCAAway trial – Abiraterone + olaparib combination in metastatic castration-resistant prostate cancer - https://www.asco.org/abstracts-presen... Key Clinical Takeaways ✔ EV + pembrolizumab improves event-free survival in muscle-invasive bladder cancer ✔ Belzutifan combinations show promising activity in renal cell carcinoma ✔ Combination PARP inhibitor + ARPI therapy may significantly extend survival in selected mCRPC patients A must-watch for oncologists and trainees looking for clear, clinically relevant takeaways from the latest GU oncology trials presented at ASCO GU26. 🎧 LISTEN ON OTHER PLATFORMS: 🔹 Spotify: https://bit.ly/ExpertInsights_EP1_Spo... 🔹 Apple Podcasts: https://apple.co/4d4gdAl 📌 CHAPTERS & TIMESTAMPS 🎙 00:08 – Introduction 👨‍⚕️ 00:14 – Meet Dr. Yüksel Ürün 🧬 00:20 – KEYNOTE-B15: EV + Pembrolizumab in Muscle-Invasive Bladder Cancer 📊 02:30 – Event-Free Survival & Pathologic Response Results ⚕️ 05:18 – LITESPARK-011: Belzutifan + Lenvatinib in RCC 📈 06:20 – Progression-Free Survival Improvement 💊 08:47 – LITESPARK-022: Adjuvant Belzutifan + Pembrolizumab 📉 10:01 – Disease-Free Survival Outcomes 🧪 11:34 – BRCAAway Trial: PARP + ARPI Combination 📊 13:00 – Survival Benefit in HRD-Mutated Prostate Cancer 🔬 15:16 – Clinical Implications for Practice 👋 15:24 – Closing Thoughts 📢 JOIN THE CONVERSATION! ❓Drop your thoughts in the comments below! 📲 Oncology at your fingertips. Download the ONCOassist app: 📥 iOS: https://apple.co/4iuMxfS 📥 Android: https://bit.ly/oncoassistonandroid 📥Webapp: https://bit.ly/ONCOassistOnWeb 🚀 SUBSCRIBE to the ONCOassist Youtube Channel for more expert insights! 🔔 Turn on notifications so you never miss an episode. 📌 FOLLOW US FOR UPDATES: 📍 LinkedIn: https://bit.ly/oncoassistlinkedin 📍 Twitter/X: https://bit.ly/oncoassisttwitter #OncologySpotlight #ExpertInsights #ASCOGU #MedicalOncology #BladderCancer #KidneyCancer #ProstateCancer #OncologyEducation #CancerResearch #PrecisionOncology #ONCOassist #GU26 #Oncology Podcast